Codexis
Latest round
- Series D
Last raised
- Nov 2007
Total raised
- $5M
Investors
- 6
About Codexis
Founded in 2002 and based in California, US, Codexis, Inc. is a biotechnology company that focuses on developing engineered proteins for use in various industries such as pharmaceuticals, biotherapeutics, food and beverages, and molecular diagnostics. In February 2024, Codexis, Inc. The company is publicly listed on Nasdaq under the ticker symbol CDXS. As of July 204, Stephen Dilly is the CEO of the company. Codexis, Inc. offers a range of products and services centered around engineered enzymes for various applications. These include biocatalysts for efficient pharmaceutical manufacturing, IVT enzymes for high-quality mRNA production, and enzymes for next-generation sequencing (NGS) library preparation. Codexis also provides PCR and LAMP enzymes for nucleic acid detection and custom enzyme development services, assisting partners in creating solutions for specific needs. The company’s products are designed to enhance process efficiency, improve yields, and support innovation across pharmaceutical, RNA manufacturing, and life science research industries.
Who invested in Codexis
6 investors across 1 round
See all investors in Codexis
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series D
Nov 13, 2007
Amount
$5M
Investors
Questions about Codexis
Who invested in Codexis?
Codexis has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Codexis raised?
Codexis has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Codexis last raise money?
Codexis's most recent round on record is a Series D, in Nov 2007.
What does Codexis do?
Founded in 2002 and based in California, US, Codexis, Inc.
Where is Codexis headquartered?
Codexis is headquartered in Redwood City, US.
Which VCs invest in companies like Codexis?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Codexis's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Codexis? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.